Abstract Number: 0139 • ACR Convergence 2022
A Clinical Study Designed to Support a Demonstration of Interchangeability Between AVT02 and Reference Adalimumab (Humira®)
Background/Purpose: To support a demonstration of interchangeability of proposed biosimilar AVT02 and Humira® (reference adalimumab).Methods: Participants with chronic plaque psoriasis were selected for the study…Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…Abstract Number: 0254 • ACR Convergence 2022
Lipids and Vascular Inflammation in Patients with RA Using Triple Therapy vs Methotrexate + TNFi: A Secondary Analysis of the TARGET Randomized Active Comparator Trial
Background/Purpose: Rheumatoid arthritis (RA) treatments are known to cause complex changes in lipids, in part by controlling disease activity. While there are robust data on…Abstract Number: 1505 • ACR Convergence 2022
Blue-collar Workers with Psoriatic Arthritis: Disease Activity, Work Disability and Response to Biologics
Background/Purpose: Biomechanical stress is a possible trigger of inflammation in psoriatic arthritis (PsA). The influence of physically demanding occupations on this potential association has not…Abstract Number: 0302 • ACR Convergence 2022
Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis
Background/Purpose: To compare infectious risk between JAK inhibitors (JAKi) versus TNF inhibitors (TNFi) among patients with rheumatoid arthritis (RA) in Korea. Methods: Using 2009-2019 Korea…Abstract Number: 1510 • ACR Convergence 2022
Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries
Background/Purpose: In axial spondyloarthritis (axSpA) much attention has been focused on pharmacological management, including tumour necrosis factor inhibitors (TNFi), as a means to reducing inflammation,…Abstract Number: 0306 • ACR Convergence 2022
Maintenance of Disease Activity and Treatment Persistence in Patients with Rheumatoid Arthritis Who Switched from Combination to TNF Inhibitor Monotherapy: Results from the Rheumatology Informatics System for Effectiveness (RISE) Registry
Background/Purpose: Data regarding the maintenance of disease activity (DA) and treatment persistence in patients (pts) who switched from combination therapy to monotherapy for the management…Abstract Number: 1553 • ACR Convergence 2022
Effectiveness and Safety of Adalimumab versus Leflunomide in Patients with Takayasu Arteritis – a Retrospective Cohort Study
Background/Purpose: Therapy for Takayasu arteritis (TAK) is based on the combination of high-dose glucocorticoids and immunosuppressive and/or biologic agents. Patients presenting severe disease manifestations are…Abstract Number: 0417 • ACR Convergence 2022
Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Literature Review
Background/Purpose: The ASAS-SPEAR (SPondyloarthritis EARly definition) project aims to develop a consensual definition of early SpA. Therefore, it is important to know whether treatment earlier…Abstract Number: 2196 • ACR Convergence 2022
Risk Factors for Severe COVID-19 Outcomes: A Study of Immune-mediated Inflammatory Diseases, Immunomodulatory Medications, Vaccination Status, and Comorbidities in a Large US Healthcare System
Background/Purpose: Reported infection rates and severe outcomes of COVID-19 in patients with immune-mediated inflammatory diseases (IMIDs) and their therapy, have varied depending on the nature…Abstract Number: 0418 • ACR Convergence 2022
Real World Evidence on Disease Activity in Patients with Ankylosing Spondylitis Treated with Tumour Necrosis Factor Inhibitors and/or Nonsteroidal Anti-Inflammatory Drugs in Routine Care
Background/Purpose: Ankylosing Spondylitis (AS) is an inflammatory rheumatic disease affecting the axial skeleton (1), with a prevalence of up to 0.5% in Europe (2; 3),…Abstract Number: 2215 • ACR Convergence 2022
Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…Abstract Number: 0422 • ACR Convergence 2022
Efficacy and Safety of Secukinumab in the Treatment of Axial Spondyloarthritis: Real-Life Data from TURKBIO Cohort
Background/Purpose: In this study, we aimed to evaluate the results of secukinumab treatment in patients with Axial Spondyloarthritis (AxSpA) who were enrolled in the TURKBIO…Abstract Number: 0424 • ACR Convergence 2022
The Efficacy and Safety of CT-P13 as First-line and Subsequent-line Therapy in Patients with Ankylosing Spondylitis: Real-life Data from TURKBIO Cohort
Background/Purpose: In this study, it was aimed to evaluate the long-term drug survival, efficacy and safety of infliximab biosimilar CT-P13 in Turkish patients diagnosed with…Abstract Number: 0774 • ACR Convergence 2022
HLA-DQ2 Is Associated with Anti-drug Antibody Formation to Infliximab Across Immune-mediated Inflammatory Diseases
Background/Purpose: Immunogenicity is a leading cause of treatment failure to TNF inhibitors, and also affects drug safety. Variations in HLA class II genes have been…
ACR Meeting Abstracts